Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAS825 in COVID-19 pneumonia
NCT04382651Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in COVID-19 pneumonia comparing MAS825 + SoC with Placebo + SoC (2 arms). Primary endpoint: APACHE II Severity of Disease at Day 15. Started Jun 2020; status: completed.
02
Drugs
MAS825
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04382651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382651.